These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30506139)

  • 1. Dacomitinib: First Global Approval.
    Shirley M
    Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
    Nagano T; Tachihara M; Nishimura Y
    Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
    Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
    Lau SCM; Batra U; Mok TSK; Loong HH
    Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
    Sun H; Wu YL
    Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
    Santarpia M; Menis J; Chaib I; Gonzalez Cao M; Rosell R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):831-840. PubMed ID: 31356117
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
    Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dose modifications on the safety and efficacy of dacomitinib for
    Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
    Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
    Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
    BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobocertinib: First Approval.
    Markham A
    Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib.
    Kudo K; Kawakado K; Kawajiri T; Nishi T; Makimoto G; Tamura T; Kuyama S; Tanimoto M
    Intern Med; 2020 Jul; 59(14):1739-1740. PubMed ID: 32296006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib: first global approval.
    Dungo RT; Keating GM
    Drugs; 2013 Sep; 73(13):1503-15. PubMed ID: 23982599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
    Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
    Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
    Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.